Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report

A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (−10.3%) for 6 months and the reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Farinha, Juliano Boufleur, Weinert, Letícia Schwerz, Costa, Lidiane Pozza, Costa, Marcelo Zanusso, de Peres, Patrícia Peres, Lorea, Cláudia Fernandes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042659/
https://www.ncbi.nlm.nih.gov/pubmed/35495777
http://dx.doi.org/10.1007/s13410-022-01076-1
Descripción
Sumario:A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (−10.3%) for 6 months and the reduction of glycated hemoglobin A(1c).

Ejemplares similares